Deltex Medical Group plc (LON:DEMG), the global leader in oesophageal Doppler monitoring (“ODM”) today announced the release and first sales of its new High Definition Impedance Cardiography (HD-ICG) modality in France.
The Company released the French language version of the HD-ICG module on its CardioQ-ODM+ haemodynamic monitoring platform earlier this month and supported clinical demonstrations to key opinion leaders in France. Following the success of these evaluations, the Company’s distributor in France has placed a small initial order, purchasing two HD-ICG consoles for demonstration purposes.
HD-ICG provides a continuous indirect, non-invasive measurement of central blood flow using disposable single patient sensor sets. The sensors are connected to the Deltex CardioQ-ODM+ platform via a small console which also provides power; values are displayed on specially designed screens on the Deltex monitor. It is ideally suited to awake patients in both critical care and surgery who do not tolerate ODM probes.
The Company expects to make margins of around 35% to 40% on sales to European distributors of both HD-ICG consoles and subsequent disposable sensor sets.
Ewan Phillips, Deltex Medical Group Plc Chief Executive, commented: “We are delighted to have made the first sales of our HD-ICG module into France, which is, by volume of patients treated, our largest export market. We plan to release this new module into additional select overseas markets over the remainder of the year.”
